Market Currents
Shares of InterMune (ITMN +8.8%) run higher after the company announces that its lung disease...
-
Thursday, March 15, 2012, 11:16 AM ETShares of InterMune (ITMN +8.8%) run higher after the company announces that its lung disease drug Esbriet gained approval with a Germany review committee. The action clears a path for the treatment to be approved by the nation's health insurers and helps increase confidence that France will also allow the therapy.
Other date
Latest Articles
